SCHEMBL1034290

SCHEMBL1034290

Nc1cccc2ccc(-c3ccncc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
AR P10275 1/20 0.53
MAP2K3 P46734 2/20 0.46
PARP1 P09874 2/20 0.44
LMNA P02545 1/20 0.42
IMPDH2 P12268 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTR3A P46098 1/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
SRC P12931 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GMNN O75496 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033940 0.85 PARP1 (0.58) CYP3A4NPC1RAB9AMAP2K3PARP1
SCHEMBL31517113 0.85 PARP1 (0.58) CYP3A4NPC1RAB9AMAP2K3PARP1
SCHEMBL1030196 0.83 HSP90AA1 (0.54) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5958940 0.81 RAB9A (0.43) CYP3A4CYP1A2CYP2C9CYP2C19NPC1
SCHEMBL28231914 0.81 PARP1 (0.43) CYP3A4CYP2C19NPC1RAB9APARP1
SCHEMBL29496334 0.79 RAB9A (0.53) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL14428352 0.79 AR (0.53) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30590014 0.79 NPC1 (0.53) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL28722905 0.79 RAB9A (0.53) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1645282 0.77 CYP1A2 (0.54) CYP3A4CYP1A2CYP2C9CYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 CYP3A4 2193/4885CYP1A2 2055/4885CYP2D6 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.